Cryolife FibRx bioadhesive clinicals to begin by "early fall," CEO Anderson predicts.
This article was originally published in The Gray Sheet
Executive Summary
CRYOLIFE FIBRX BIOADHESIVE U.S. CLINICAL TRIALS expected to begin in late summer or early fall of this year, Cryolife President and CEO Steven Anderson told analysts May 25 at a meeting of the New York Society of Security Analysts in New York City. The study will evaluate the ability of the biodegradable bioadhesive to improve healing of skin grafts for second- and third-degree burns.